News headlines about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.4439792002757 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several equities analysts recently issued reports on AXSM shares. BTIG Research started coverage on Axsome Therapeutics in a research report on Friday, May 19th. They issued a “buy” rating and a $14.00 price objective for the company. Zacks Investment Research raised Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Wednesday, May 24th. Aegis reiterated a “buy” rating and set a $20.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, May 25th. ValuEngine upgraded Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $31.00 price objective (up previously from $28.00) on shares of Axsome Therapeutics in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Axsome Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.08.

Shares of Axsome Therapeutics (NASDAQ:AXSM) traded up 3.51% during mid-day trading on Tuesday, hitting $5.90. The stock had a trading volume of 74,366 shares. The stock’s market cap is $139.27 million. Axsome Therapeutics has a 12 month low of $3.53 and a 12 month high of $9.11. The firm has a 50 day moving average price of $5.41 and a 200-day moving average price of $4.57.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, equities research analysts forecast that Axsome Therapeutics will post ($1.43) EPS for the current year.

WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Axsome Therapeutics (AXSM) Stock Price” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with's FREE daily email newsletter.